Info

Idera Pharmaceuticals, Inc. (Idera) is a biotechnology company engaged in the discovery and development of synthetic deoxyribonucleic acid (DNA)-and ribonucleic acid (RNA)-based drug candidates targeted to Toll-Like Receptors (TLRs), to treat infectious diseases, autoimmune diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. TLRs are specific receptors present in immune system cells that recognize the DNA or RNA of pathogens, such as bacteria or viruses and initiate an immune response. IMO-2125, a TLR9 agonist, is the Company lead drug candidate for infectious diseases. As of December 31, 2007, Idera conducted a Phase I clinical trial of IMO-2125 in patients with chronic hepatitis C virus infection who have not responded to current standard of care therapy. As part of the Company’s infectious disease program, it is also evaluating RNA-based compounds that act as agonists of TLR7 and TLR8.(Source: 10-K)